Synlogic (NASDAQ:SYBX) Shares Pass Below Fifty Day Moving Average – Here’s Why

Shares of Synlogic, Inc. (NASDAQ:SYBXGet Free Report) crossed below its fifty day moving average during trading on Tuesday . The stock has a fifty day moving average of $1.37 and traded as low as $1.26. Synlogic shares last traded at $1.31, with a volume of 3,567 shares traded.

Synlogic Trading Down 1.5 %

The stock has a 50-day simple moving average of $1.37 and a 200-day simple moving average of $1.42. The company has a market cap of $15.32 million, a price-to-earnings ratio of -0.31 and a beta of 0.72.

Synlogic (NASDAQ:SYBXGet Free Report) last announced its quarterly earnings data on Thursday, March 6th. The biotechnology company reported ($0.06) earnings per share for the quarter, beating the consensus estimate of ($0.10) by $0.04. As a group, research analysts expect that Synlogic, Inc. will post -2.71 EPS for the current fiscal year.

Synlogic Company Profile

(Get Free Report)

Synlogic, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of synthetic biotics to treat metabolic diseases in the United States. Its pipeline include SYNB1618, an orally administered, non-systemically absorbed drug candidate to treat phenylketonuria; SYNB1934, an orally administered, non-systemically absorbed drug candidate, which is in Phase III clinical trial to treat phenylketonuria; SYNB1353, an orally administered, non-systemically absorbed drug candidate, which is in Phase I clinical to treat homocystinuria; SYNB8802, an orally administered, non-systemically absorbed drug candidate that is in Phase II clinical trial for the treatment of enteric hyperoxaluria; and SYNB2081 to lower uric acid for the potential treatment of gout.

Featured Stories

Receive News & Ratings for Synlogic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synlogic and related companies with MarketBeat.com's FREE daily email newsletter.